Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
about
Rational design of non-resistant targeted cancer therapiesInvestigation of FOXM1 as a Potential New Target for Melanoma.Electrotransfer of Plasmid DNA Encoding an Anti-Mouse Endoglin (CD105) shRNA to B16 Melanoma Tumors with Low and High Metastatic Potential Results in Pronounced Anti-Tumor Effects.Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities.Etlingera elatior Extract promotes cell death in B16 melanoma cells via down-regulation of ERK and Akt signaling pathways.Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.Naringin enhances osteogenic differentiation through the activation of ERK signaling in human bone marrow mesenchymal stem cells.Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors.The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells.A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
P2860
Q33594692-8692E90E-C4A7-4D19-847C-98ED01EF7EA3Q35861978-32FBD286-A7C8-4798-AA60-121828DB38EFQ36506981-D26D56F0-D8F8-4A5D-83A9-946B6528DDADQ38838757-C00DCDCB-0042-4276-BED2-D64A5C65DB8DQ39191984-C5A881A1-3CD9-4C7C-8F09-3A9C0D11470AQ41491478-59153A74-5D6F-4F26-9453-B86C815B2EABQ41862341-AC7F60BA-5B96-4759-AB1B-AF55907B694CQ41881607-94E6CBD8-5A3A-40AE-8427-4F21A9A89644Q46178714-27906FD2-5BB0-4174-8BD9-E9FD023344C5Q47139368-959E19A1-C9F9-415E-A79D-A0359A320904Q55339149-27406ABE-548A-4A86-8B39-1EE9D1BE575E
P2860
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@ast
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@en
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@nl
type
label
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@ast
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@en
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@nl
prefLabel
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@ast
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@en
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@nl
P2860
P356
P1476
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
@en
P2860
P356
10.3389/FONC.2015.00161
P407
P577
2015-01-01T00:00:00Z